History of pre-transplant malignancy prior to kidney transplantation has long been considered a relative contraindication for kidney transplant due to the belief that immunosuppression after transplantation would promote malignancy recurrence. There are four major issues of concern about the effects of pre-transplant malignancy on kidney transplant recipients: recurrence of primary tumors, increase of de novo malignancy, adverse effects on patient survival, and graft-specific outcomes such as rejection.

Ban et al [1] recently analyzed 3,748 patients in two Korean transplantation centers and indicated that the frequency of pre-transplant malignancy increased, and type of the malignancy changed because of introduction and dissemination of a national cancer screening system. They also reported that pre-transplant malignancy did not affect either primary tumor recurrence or de novo malignancy after kidney transplantation. Based on the results, additional discussion on pre-transplant malignancy is expected because the topic has been relatively neglected compared to other clinical issues in Korea. This study is the first to present data on pre-transplant malignancy in Korea. However, there were some limitations because the study included a relatively small number of patients and data from only two clinical centers in Korea. Therefore, careful interpretation is needed to apply these results to actual clinical practice because a variety of different outcomes have been reported on the impact of pre-transplant malignancy on post-transplant outcomes [2–7].

Most guidelines recommend that patients with a history of pre-transplant malignancy wait to receive a kidney transplant for a minimum defined time after successful treatment because of the risk of recurrence [8]. In addition, the guidelines also suggest advising patients with prior malignancy of the increased risk of de novo malignancy compared with patients that do not have a previous history of malignancy that undergo transplantation. Previous reports have indicated that kidney transplant recipients with a history of pre-transplant malignancy showed higher incidence of post-transplant de novo malignancies and higher recurrence rate after kidney transplantation [2]. However, there are limited data available to provide guidance on the suitability for performing transplants in patients with a prior malignancy, as most information has been drawn from research on Western population-based databases [3–7]. Table 1 summarizes the reported literature on clinical outcomes of transplant patients with a previous cancer [1,3–7]. However, the results are controversial, and recent studies that focus on cancer risk in kidney graft recipients with pre-transplant malignancy do not help address questions that arise in everyday clinical practice.

The reason for recommending a waiting period in patients with a history of pre-transplant malignancy is because of previous assertions that risk of post-transplant malignancy in Korea.
tumor recurrence could depend on the length of the interval between pre-transplant tumor diagnosis and renal transplantation [2]. However, recent studies have not reported strong evidence to support recommendations that longer intervals between cancer diagnosis and renal transplantation decrease the risk of tumor recurrence [7].

As Ban et al [1] suggested in their paper, the incidence of pre-transplant malignancy has changed significantly over time, and treatment approaches have also advanced and changed. Over the last decade, thyroid cancer and renal cell carcinoma (RCC) were the most frequent pre-transplant malignancy cases in Korea. Considering that there was no recurrence after transplantation in these two types of pre-transplant malignancy, it is likely that separate criteria are needed for these common types of pre-transplant malignancy. Therefore, it has become clear that special criteria are needed for thyroid cancer, which tends to be diagnosed early in medical examination or incidentally discovered during parathyroidectomy in patients with end-stage renal disease. The current guidelines for RCC also suggest that no delay is required for subjects with small or incidentally discovered RCC, while the recommendations for patients who have been treated for symptomatic RCC or for those with large or invasive tumors are conflicting. In this issue of Journal, Park et al [9] also reported that patients with early-stage and asymptomatic RCC did not require a mandatory observational period prior to kidney transplantation after curative nephrectomy.

Most researchers have suggested that patients should be individually evaluated for risk of cancer recurrence after transplantation. However, there is currently no significant prediction model that can provide parameters for overall survival and cancer-specific survival in transplanted patients. The main limitations of these tools are that most systems for prediction of clinical prognosis have not been validated in transplant patients or in any other patient group that require immunosuppressive drugs for long periods of time. Some studies have suggested that the fixed waiting time for transplantation in patients with a history of pre-transplant malignancy is no longer justified [7,10]. To date, evidence suggests that superficial cancer in the bladder, cervix, and skin and asymptomatic T1 RCC do not require a waiting period for kidney transplantation, although some invasive tumors should be avoided because of a high risk of recurrence or metastasis after transplantation [8].

Based on current and emerging research, patients should be individually evaluated for risk of cancer recurrence, expected survival, and quality of life. The possibility of increased risk of developing de novo malignancy should be discussed with patients as well as physicians. However, in the context of rapidly developing diagnostic tools and treatment advancements in current clinical practice, further research and guidelines need to be developed for renal transplantation in patients with a history of pre-transplant malignancy.
Conflicts of interest

The author has no conflicts of interest to declare.

References

[1] Ban TH, Park WY, Jin K, et al. Changing pattern and safety of pretransplant malignancy in kidney transplant recipients. *Kidney Res Clin Pract* 2019;38:509-516.

[2] Penn I. Evaluation of transplant candidates with pre-existing malignancies. *Ann Transplant* 1997;2:14-17.

[3] Webster AC, Craig JC, Simpson JM, Jones MP, Chapman JR. Identifying high risk groups and quantifying absolute risk of cancer after kidney transplantation: a cohort study of 15,183 recipients. *Am J Transplant* 2007;7:2140-2151.

[4] Brattström C, Granath F, Edgren G, Smedby KE, Wilczek HE. Overall and cause-specific mortality in transplant recipients with a pretransplantation cancer history. *Transplantation* 2013;96:297-305.

[5] Farrugia D, Mahboob S, Cheshire J, et al. Malignancy-related mortality following kidney transplantation is common. *Kidney Int* 2014;85:1395-1403.

[6] Dahle DO, Grotmol T, Leivestad T, et al. Association between pretransplant cancer and survival in kidney transplant recipients. *Transplantation* 2017;101:2599-2605.

[7] Unterrainer C, Opelz G, Döhler B, Süsal C; Collaborative Transplant Study. Pretransplant cancer in kidney recipients in relation to recurrent and de novo cancer incidence posttransplantation and implications for graft and patient survival. *Transplantation* 2019;103:581-587.

[8] Chadban SJ, Barraclough KA, Campbell SB, et al.; Kidney Health Australia Caring for Australians with Renal Impairment (KHA-CARI). KHA-CARI guideline: KHA-CARI adaptation of the KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients. *Nephrology (Carlton)* 2012;17:204-214.

[9] Park KH, Yoon JA, Kim HS, et al. Clinical features and outcomes in kidney transplant recipients with renal cell carcinoma: a single-center study. *Kidney Res Clin Pract* 2019;38:517-524.

[10] Nguyen KA, Syed JS, Luciano R, Shuch B, Vourganti S. Optimizing waiting duration for renal transplants in the setting of renal malignancy: is 2 years too long to wait? *Nephrol Dial Transplant* 2017;32:1767-1773.